methyltestosterone (Android, Testred, Metandren, Oretan, Virilon)
Jump to navigation
Jump to search
Introduction
Tradenames: Android, Testred, Metandren, Oretan, Virilon. DEA-controlled substance: class 3
Indications
- androgen insufficiency
- replacement therapy in hypogonadism & delayed puberty (male)
- cryptorchidism
- anorchia
- Klinfelter's syndrome[5]
- impotence (male)
- inoperable breast cancer
- LHRH deficiency[5]
- scrotal pain/mass[5]
Contraindications
Caution:
- liver or kidney disease
- heart disease
- prepubertal patients: may accelerate bone maturation without compensatory gain in linear growth
- REF 4 DOES NOT RECOMMEND USE; USE TESTOSTERONE INSTEAD
Dosage
- hypogonadism: 10-40 mg PO QD
- postpubertal cryptorchism: 30 mg QD
- inoperabable breast cancer: 50-200 mg/day
- buccal tablet should not be chewed or swallowed
Tabs: 10 & 25 mg
Monitor
- radiographic exam of wrist & hand every 6 months to assess bone maturation & epiphyseal centers in prepubertal patients
Adverse effects
- common (> 10%)
- edema, acne
- Males: virilism, priapism
- Females: virilism, amenorrhea, breast tenderness
- less common (1-10%)
- GI irritation, nausea/vomiting, hepatic dysfunction
- Males: prostatic hypertrophy, prostate cancer, impotence
- Females: hirsutism
- uncommon (< 1%)
- males
- gynecomastia
- excessive frequency & duration of penile erections
- male pattern baldness
- retention of water & electrolytes
- suppression of clotting factors
- females
- amenorrhea
- deepening of voice
- clitoral enlargement
Drug interactions
- may increase anticoagulant effect of warfarin
- imipramine in combination may result in paranoid response
Mechanism of action
More general terms
Component of
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 - not on National VA formulary
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Prescriber's Letter 10(8):46 2003
- ↑ 5.0 5.1 5.2 5.3 5.4 Deprecated Reference